ID   CMM1
AC   CVCL_0C75
SY   CMM-1; Pu; Canine Malignant Melanoma 1
DR   Wikidata; Q54813804
RX   PubMed=11217070;
RX   PubMed=24035468;
RX   PubMed=27292541;
RX   PubMed=28283079;
CC   Doubling time: 18.4 +- 1.96 hours (PubMed=11217070).
CC   Sequence variation: Mutation; VGNC; VGNC:38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468).
CC   Derived from site: In situ; Oral cavity; UBERON=UBERON_0000167.
CC   Breed/subspecies: Toy Poodle; VBO=VBO_0201061.
DI   NCIt; C185639; Canine oral melanoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Male
AG   12Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 12
//
RX   PubMed=11217070; DOI=10.1292/jvms.63.83;
RA   Ohashi E., Hong S.-H., Takahashi T., Nakagawa T., Mochizuki M.,
RA   Nishimura R., Sasaki N.;
RT   "Effect of retinoids on growth inhibition of two canine melanoma cell
RT   lines.";
RL   J. Vet. Med. Sci. 63:83-86(2001).
//
RX   PubMed=24035468; DOI=10.1016/j.tvjl.2013.08.003;
RA   Ito K., Kobayashi M., Kuroki S., Sasaki Y., Iwata T., Mori K.,
RA   Kuroki T., Ozawa Y., Tetsuka M., Nakagawa T., Hiroi T., Yamamoto H.,
RA   Ono K., Washizu T., Bonkobara M.;
RT   "The proteasome inhibitor bortezomib inhibits the growth of canine
RT   malignant melanoma cells in vitro and in vivo.";
RL   Vet. J. 198:577-582(2013).
//
RX   PubMed=27292541; DOI=10.1111/jvp.12336;
RA   Kuroki S., Kobayashi M., Tani H., Miyamoto R., Kurita S., Tamura K.,
RA   Ono K., Washizu T., Bonkobara M.;
RT   "Selective growth inhibition by suppression of F1Fo ATPase in canine
RT   malignant melanoma cell lines.";
RL   J. Vet. Pharmacol. Ther. 40:101-104(2017).
//
RX   PubMed=28283079; DOI=10.1016/j.tvjl.2017.02.001;
RA   Yoshitake R., Saeki K., Watanabe M., Nakaoka N., Ong S.M.,
RA   Hanafusa M., Choisunirachon N., Fujita N., Nishimura R., Nakagawa T.;
RT   "Molecular investigation of the direct anti-tumour effects of
RT   nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell
RT   lines.";
RL   Vet. J. 221:38-47(2017).
//